Forsbach-Sánchez G, Tamez-Pérez HE, Hernández-Herrera R, Bafidis-Lechuga B

Language: Spanish
References: 13
Page: 307-310
PDF size: 87.05 Kb.

ABSTRACT

Objective: management of macroprolactinomas in women who plan to get pregnant is controversial and when this happen there is a risk of pituitary enlargement, if this happens bromocriptine has a safe profile to be used during pregnancy, but if it is not tolerated cabergoline is a good alternative.
Clinical cases: we describe two patients with macroprolactinomas who intended to get pregnant. One of them had been previously treated surgically and the second one was treated with bromocriptine and got pregnant before the tomographic studies were checked. Both patients developed during pregnancy symptoms of macroprolactinoma enlargement and were initially treated with bromocriptine but was not tolerated and were switched to cabergoline. Both pregnancies ended with a normal full term newborn.
Conclusion: pregnant women with symptoms of pituitary enlargement must be treated with bromocriptine, but if it is not tolerated cabergoline is a good choice.

REFERENCES

1. Crosignani PG. Current treatment issues in female hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 2006;125(2):152-64.

2. Shriravastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long term-follow up. J Neurosurg 2002;97(2):299-306.

3. Berinder K, Stackenas T, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinemia in 271 women: up to three decades of clinical follow up. Clin Endocr 2005;63(4):450-455.

4. Ciccarelli A, Guerra E, De Rosa M, Milone S, Zarrilli S, Lombardi G, et al. PRL secreting adenomas in male patients. Pituitary 2005; 8(1):39-42.

5. Davis JRE. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol 2004;16(4):331-337.

6. Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med 1998;129(6):472-483.

7. Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003; 42(7):633-645.

8. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(12 Suppl): 1121-1126.

9. Randeva SH, Davies M, Prelevic GM. Prolactinoma and pregnancy. Brit J Obstet Gynecol 2000; 107(9):1064-1068.

10. Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertil Steril 1984;41 (6):793-805.

11. Canales ES, García IC, Ruiz JE, Zárate A. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981;36(4): 524-526.

12. Guillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27(5):485-534.

13. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001;4(3):179-185.